At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
Grazoprevir (GZR) +2 moredrug
Likely dose
Grazoprevir (GZR) 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects With Chronic Hepatitis C Virus Infection Who Failed Prior Direct Acting Antiviral Therapy
In Brief
A Phase 2 clinical trial evaluating Grazoprevir (GZR), Elbasvir (EBR), and 1 other intervention for Hepatitis C Virus. Completed, enrolled 79 participants.
Detailed Summary
In this study, participants with hepatitis C virus (HCV) genotype 1 (GT1) who failed prior direct-acting antiviral (DAA) therapy will receive Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) to evaluate sustained virologic response (SVR) using this drug combination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartMay 2014
Primary CompletionMay 2015
TodayJul 2026
First PostedApr 7, 2014
Enrollment StartMay 23, 2014
Primary CompletionMay 4, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.2 years ago
Interventions
Grazoprevir (GZR)drug
100 mg oral tablet (total daily dose)
Elbasvir (EBR)drug
10 mg oral capsule (total daily dose = 5 capsules)
Ribavirin (RBV)drug
200 mg oral capsule (total daily dose = 4-7 capsules)